A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose, Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability Study of CTP-499 in Healthy Adults

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose, Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability Study of CTP-499 in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs CTP 499 (Primary) ; CTP 499 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; First in man
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2016 Results published in the Clinical Pharmacology in Drug Development.
    • 19 Oct 2011 Results were presented at the American Society of Nephrology's (ASN) Kidney Week 2011, according to a Concert Pharmaceuticals media release.
    • 22 Jun 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top